Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy
Abstract This retrospective study was designed to investigate the impact of metformin use on the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. It is a retrospective, single institution study. Patients with rectal adenocarcinoma treated at Chang Gung Memor...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-10768-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235408872800256 |
|---|---|
| author | Nai-Yu Lin Kun-Yu Tsai Yen-Lin Huang Bor-Kang Jong Zhen-Hao Yu Ching-Chung Cheng Shu-Huan Huang Jeng-Fu You I-Li Lai |
| author_facet | Nai-Yu Lin Kun-Yu Tsai Yen-Lin Huang Bor-Kang Jong Zhen-Hao Yu Ching-Chung Cheng Shu-Huan Huang Jeng-Fu You I-Li Lai |
| author_sort | Nai-Yu Lin |
| collection | DOAJ |
| description | Abstract This retrospective study was designed to investigate the impact of metformin use on the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. It is a retrospective, single institution study. Patients with rectal adenocarcinoma treated at Chang Gung Memorial Hospital between January 2005 and December 2019 were retrospectively reviewed. Patients were divided into two groups: metformin users (n = 56) and non-metformin users (n = 33). The primary outcome of this study was tumor regression grade (TRG). Secondary outcomes included recurrence rate, T downstage, and disease-free survival (DFS). Patients in the metformin group demonstrated significantly improved tumor regression grade (p = 0.006). However, no significant difference was observed between the two groups in terms of overall survival (OS) or DFS. Further analysis suggested a potential association between metformin dosage and TRG. Metformin appears to influence the response to neoadjuvant chemoradiotherapy in rectal cancer, specifically impacting TRG. Further research is warranted to validate these findings and explore the optimal metformin dosage and treatment regimens. |
| format | Article |
| id | doaj-art-d42ca3b6397c43edba44c0fffdd52646 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-d42ca3b6397c43edba44c0fffdd526462025-08-20T04:02:46ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-10768-7Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapyNai-Yu Lin0Kun-Yu Tsai1Yen-Lin Huang2Bor-Kang Jong3Zhen-Hao Yu4Ching-Chung Cheng5Shu-Huan Huang6Jeng-Fu You7I-Li Lai8Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, New Taipei Municipal TuCheng HospitalDepartment of Anatomic Pathology, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouDivision of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at LinkouAbstract This retrospective study was designed to investigate the impact of metformin use on the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. It is a retrospective, single institution study. Patients with rectal adenocarcinoma treated at Chang Gung Memorial Hospital between January 2005 and December 2019 were retrospectively reviewed. Patients were divided into two groups: metformin users (n = 56) and non-metformin users (n = 33). The primary outcome of this study was tumor regression grade (TRG). Secondary outcomes included recurrence rate, T downstage, and disease-free survival (DFS). Patients in the metformin group demonstrated significantly improved tumor regression grade (p = 0.006). However, no significant difference was observed between the two groups in terms of overall survival (OS) or DFS. Further analysis suggested a potential association between metformin dosage and TRG. Metformin appears to influence the response to neoadjuvant chemoradiotherapy in rectal cancer, specifically impacting TRG. Further research is warranted to validate these findings and explore the optimal metformin dosage and treatment regimens.https://doi.org/10.1038/s41598-025-10768-7MetforminRectal cancerNeoadjuvant chemoradiotherapyTumor regression grade |
| spellingShingle | Nai-Yu Lin Kun-Yu Tsai Yen-Lin Huang Bor-Kang Jong Zhen-Hao Yu Ching-Chung Cheng Shu-Huan Huang Jeng-Fu You I-Li Lai Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy Scientific Reports Metformin Rectal cancer Neoadjuvant chemoradiotherapy Tumor regression grade |
| title | Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| title_full | Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| title_fullStr | Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| title_full_unstemmed | Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| title_short | Metformin’s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| title_sort | metformin s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy |
| topic | Metformin Rectal cancer Neoadjuvant chemoradiotherapy Tumor regression grade |
| url | https://doi.org/10.1038/s41598-025-10768-7 |
| work_keys_str_mv | AT naiyulin metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT kunyutsai metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT yenlinhuang metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT borkangjong metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT zhenhaoyu metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT chingchungcheng metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT shuhuanhuang metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT jengfuyou metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy AT ililai metforminsimpactontumorregressiongradeindiabeticpatientswithrectalcancerundergoingneoadjuvantchemoradiotherapy |